Abstract
PURPOSE: To report intravitreal triamcinolone acetonide for idiopathic cystoid macular edema (ICME). DESIGN: Interventional case series. METHODS: Two patients with ICME were treated with intravitreal triamcinolone. RESULTS: In one patient, best-corrected acuity was 20/70 before treatment and 20/30 6 months posttreatment in both eyes. Foveal thickness was 606 μm before and 197 μm posttreatment in the right eye and 542 μm before and 190 μm posttreatment in the left eye. In another patient, best-corrected acuity was 20/200 before treatment and 20/50 5 months posttreatment; foveal thickness was 580 μm before and 208 μm posttreatment. Recurrence of macular edema responded to repeat intravitreal triamcinolone acetonide in both patients. CONCLUSIONS: Intravitreal triamcinolone may be associated with reduced edema and improved vision in patients with ICME; however, these changes may be transient.
| Original language | English |
|---|---|
| Pages (from-to) | 737-739 |
| Number of pages | 3 |
| Journal | American Journal of Ophthalmology |
| Volume | 136 |
| Issue number | 4 |
| DOIs | |
| State | Published - Oct 1 2003 |
Fingerprint
ASJC Scopus subject areas
- Ophthalmology
Cite this
Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema. / Scott, Ingrid U.; Flynn, Harry W; Rosenfeld, Philip J.
In: American Journal of Ophthalmology, Vol. 136, No. 4, 01.10.2003, p. 737-739.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema
AU - Scott, Ingrid U.
AU - Flynn, Harry W
AU - Rosenfeld, Philip J
PY - 2003/10/1
Y1 - 2003/10/1
N2 - PURPOSE: To report intravitreal triamcinolone acetonide for idiopathic cystoid macular edema (ICME). DESIGN: Interventional case series. METHODS: Two patients with ICME were treated with intravitreal triamcinolone. RESULTS: In one patient, best-corrected acuity was 20/70 before treatment and 20/30 6 months posttreatment in both eyes. Foveal thickness was 606 μm before and 197 μm posttreatment in the right eye and 542 μm before and 190 μm posttreatment in the left eye. In another patient, best-corrected acuity was 20/200 before treatment and 20/50 5 months posttreatment; foveal thickness was 580 μm before and 208 μm posttreatment. Recurrence of macular edema responded to repeat intravitreal triamcinolone acetonide in both patients. CONCLUSIONS: Intravitreal triamcinolone may be associated with reduced edema and improved vision in patients with ICME; however, these changes may be transient.
AB - PURPOSE: To report intravitreal triamcinolone acetonide for idiopathic cystoid macular edema (ICME). DESIGN: Interventional case series. METHODS: Two patients with ICME were treated with intravitreal triamcinolone. RESULTS: In one patient, best-corrected acuity was 20/70 before treatment and 20/30 6 months posttreatment in both eyes. Foveal thickness was 606 μm before and 197 μm posttreatment in the right eye and 542 μm before and 190 μm posttreatment in the left eye. In another patient, best-corrected acuity was 20/200 before treatment and 20/50 5 months posttreatment; foveal thickness was 580 μm before and 208 μm posttreatment. Recurrence of macular edema responded to repeat intravitreal triamcinolone acetonide in both patients. CONCLUSIONS: Intravitreal triamcinolone may be associated with reduced edema and improved vision in patients with ICME; however, these changes may be transient.
UR - http://www.scopus.com/inward/record.url?scp=0141793634&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0141793634&partnerID=8YFLogxK
U2 - 10.1016/S0002-9394(03)00266-6
DO - 10.1016/S0002-9394(03)00266-6
M3 - Article
C2 - 14516818
AN - SCOPUS:0141793634
VL - 136
SP - 737
EP - 739
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
SN - 0002-9394
IS - 4
ER -